Oren M. Becker

Dynamix Pharmaceuticals Ltd. discovers and develops small-molecule drugs for treating cancer and autoimmune disorders. It focuses its discovery on cancer metabolism modulators and type II selective kinase inhibitors. The firm offers DNX-03000 that targets Pyruvate Kinase M2 (PKM2), an enzyme that is a key mediator of cancer metabolism; and DNX-06000 that targets an undisclosed target. The company was founded by Oren M. Becker in 2009 and is headquartered in Rehovot, Israel.

Vidac Pharma Ltd. manufactures pharmaceutical products. It is a clinical stage biopharmaceutical company dedicated to discovering and developing first-in-class medicines to help people suffering from a range of oncologic and dermatologic diseases. The company was founded in 2011 by Max Herzberg is headquartered in Jerusalem, Israel.

EPIX Pharmaceuticals, Inc. used to develop targeted contrast agents both to improve the capability and expand the use of magnetic resonance imaging (MRI) as a tool for diagnosing human disease. The company was founded in 1988 and was headquartered in Lexington, MA.

Predix Pharmaceuticals Holdings, Inc. is a pharmaceutical company focused on the discovery and development of novel, highly selective, small-molecule drugs that target G-Protein Coupled Receptors (GPCRs) and ion channels.

Tel-Aviv University operates as a university in Israel. Its faculties include arts, engineering, science, humanities, law, life science, management, medicine, and social science. The company was founded in 1956 and is headquartered in Ramat Aviv, Israel.

Predix Pharmaceuticals, Inc. develops novel drugs and other related products. It is a clinical stage drug development company that uses proprietary discovery and lead optimization engine to develop novel drugs for G-protein coupled receptor (GPCR) and ion channel targets. The company was founded by Silvia Noiman, Haim Aviv, Oren M. Becker and Oren M. Ramot in September, 2002 and is headquartered in Woburn, MA.